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Abstract
Background: TC-2559 is a selective a4b2 subtype of nicotinic acetylcholine receptor (nAChR) partial agonist and
a4b2 nAChR activation has been related to antinociception. The aim of this study is to investigate the analgesic
effect of TC-2559 and its underlying spinal mechanisms.
Results: 1) In vivo bioavailability study: TC-2559 (3 mg/kg) had high absorption rate in rats with maximal total brain
concentration reached over 4.6 μM within first 15 min after administration and eliminated rapidly with brain half
life of about 20 min after injection. 2) In vivo behavioral experiments: TC-2559 exerts dose dependent
antinociceptive effects in both formalin test in mice and chronic constriction injury (CCI) model in rats by
activation of a4b2 nAChRs; 3) Whole-cell patch-clamp studies in the superficial dorsal horn neurons of the spinal
cord slices: perfusion of TC-2559 (2 μM) significantly increased the frequency, but not amplitude of spontaneous
inhibitory postsynaptic currents (sIPSCs). The enhancement of sIPSCs was blocked by pre-application of DHbE( 2
μM), a selective a4b2 nicotinic receptor antagonist. Neither the frequency nor the amplitude of spontaneous
excitatory postsynaptic currents (sEPSCs) of spinal dorsal horn neurons were affected by TC-2559.
Conclusions: Enhancement of inhibitory synaptic transmission in the spinal dorsal horn via activation of a4b2
nAChRs may be one of the mechanisms of the antinociceptive effects of TC-2559 on pathological pain models. It
provides further evidence to support the notion that selective a4b2 subtype nAChR agonist may be developed as
new analgesic drug for the treatment of neuropathic pain.
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Background
Opioids and the nonsteroidal anti-inflammatory drugs
(NSAIDs) are the two classes of most common used
analgesic drugs. Due to the deficiencies associated with
these two classes of compounds, exploration of novel
targeted drugs for pain relief has been the interests to
many researchers [1-3].
Nicotine, agonist of nicotinic acetylcholine receptors
(nAChRs), has long been known to have antinociceptive
effects, but failed to be developed as an analgesic agent
because of its relatively modest antinociceptive effects
and toxicities associated with nicotine [4-7]. In addition,
epibatidine, a non-selectiven A C h Ra g o n i s t ,i st h em o s t
potent pain relief ligand known so far, but with server
nicotinic type side effects [8]. Thus it will be necessary
to develop a subtype selective ligand to get an accepta-
ble therapeutic index. There are at least 12 different
subunits of neuronal nAChRs, including a2~a10 and
b2~b4 have been identified so far and these subunits
form many different subtypes of nAChRs with penta-
meric structures consisting of homomers or heteromers
[9]. Homomeric nAChRs are assembles with a subunits,
while heteromeric nAChRs comprise various combina-
tions of a and b subunits [10,11]. However, the analge-
sic effects of nAChRs related to a4b2 subtype has only
been studied with the aid of the selective antagonists
[11,12], but the direct analgesic effect of the selective
agonist of the a4b2 subtype of nAChR has not been
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any medium, provided the original work is properly cited.reported so far, due to lack of selective agonist commer-
cially available. Recently, TC-2559 has been developed
as a partial neuronal nicotinic receptor agonist [13] and
later been further profiled and characterized as a selec-
tive agonist at a4b2 subtype of nAChRs both in vitro
[14] and in vivo [14-16]. TC-2559 has an in vitro EC50
of 100 nM on a4b2-transfected HEK cells, ineffective
on a7a n da3b2 receptors up to 10 μM, and weakly
effective on a2b4, a4b4 and a3b4 receptors, with EC50’s
in the range of 10-30 μM [14]. Our previous studies
also demonstrated in vivo that TC-2559, by selectively
activation of a4b2 subtype of nAChRs, enhanced dopa-
minergic neuronal firing and suppressed of long term
potentiation of hippocampal dentate gyrus neurons in
anaesthetized rats [14-16].
In current study, a combination of in vivo animal
pathological pain models and in vitro whole-cell patch-
clamp recordings in the spinal cord slices were used to
examine the antinociceptive efficiency of TC-2559 and
its underling spinal mechanism. Our results demon-
strated that TC-2559 effectively inhibited pathological
pain in animal neuropathic pain models and enhanced
the inhibitory neurotransmission, but not excitatory
transmission, in the spinal dorsal horn via activation of
a4b2 subtype of nicotinic receptors.
Results
Brain exposure results of TC2559
I no r d e rt oi d e n t i f yt h ea p p r o p r i a t es y s t e m i cd o s ef o r
the in vivo behavioral pain model studies, TC-2559 used
in the present study was initially investigated for brain
bioavailability. Bolus dose of TC-2559 (3 mg/kg) was
injected i.p. and then the total brain concentrations
were measured at 0.25, 0.5, 1 and 2 hours after adminis-
tration. TC-2559 was rapidly absorbed following i.p.
administration, with maximum brain concentrations of
about 4.6 μM achieved 15 minutes after dosing. The
clearance of the compound from brain was very rapid,
with a half life of about 20 minutes and almost totally
eliminated about 2 h after injection (Figure 1). This
result is very similar to that we previously reported by
intravenous TC-2559 administration [16]. Thus, the
brain (as well as spinal cord) concentration of TC-2559
achieved by i.p. administration of 3 mg/kg dose is suffi-
cient for activation of a4b2 subtype of nicotinic
receptors.
TC-2559 dose dependently reduced acute formalin-
induced biphasic nociceptive responses in mice
The formalin test for nociception, which is widely used
and easier to perform, involves moderate, continuous
pain generated by injured tissue. It is a useful model,
particularly for the screening of novel compounds, since
it encompasses inflammatory, neurogenic, and central
mechanisms of nociception [17,18]. Thus the effect of
TC-2559 on formalin test was first examined.
Unilateral intraplantar injection of diluted formalin
(5%) induced characteristic biphasic nociceptive beha-
viour responses: the first phase lasted for ~5 min and
the second phase was between 10 to 40 min (Figure
2A), similar as we previously reported [19]. TC-2559 (1,
3, 10 mg/kg, i.p.) dose dependently reduced both early
and late phases of formalin induced nociceptive beha-
vioral responses (Figure 2A). In compared to the saline
control group (n = 6), TC-2559 had no significant anti-
nociceptive effect at low dose (1 mg/kg, n = 5), but sig-
nificantly inhibited formalin induced pain behavior at
higher doses tested (3 and 10 mg/kg, n = 5 for both
groups) (P < 0.001, two-way ANOVA) (Figure 2B).
These results demonstrated that TC-2559 has dose
dependent analgesic property in mouse formalin pain
models.
TC-2559 dose dependently inhibited CCI-induced
neuropathic pain in rats
The chronic constriction injury (CCI) model is one of
the best-characterized behavioral models for neuropathic
pain in rats [20]. To further examine whether TC-2559
contributes to the neuropathic pain, TC-2559 was tested
on rat CCI models. Consistent with a previous study
[19], unilateral CCI operation induced robust mechani-
cal allodynia, reached mechanical sensitivity of lower
than 2 g, between 7 to 9 days on the ipsilateral hind
paw, but without effect on the contralateral hindpaw in
Figure 1 The brain bioavailability of TC-2559 after systemic
administration in rat. Trace showing total brain concentration of
TC-2559 (3 mg/kg, i.p.) at the time point from 0.25 to 2 h after i.p.
injection (The line represented the average volumes from two
animals).
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= 38) on ipsilatral hindpaw were discarded from the
further pharmacological study. The allodynia induced by
CCI were persisted for weeks in the ipsilateral hindpaw,
as shown in Figure 3A (P < 0.001, n = 6).
Drugs were tested on rats with stable allodynia
(mechanical sensitivity lower than 2 g) after CCI. Base-
line mechanical sensitivity was measured 10 min before
drug injection and saline was served as vehicle control.
On ipsilateral hind paw, TC-2559 (i.p.) dose dependently
reversed CCI induced allodynia in comparison with sal-
ine control. TC-2559 at doses of 1 mg/kg (n = 6) and 3
mg/kg (n = 6) both significantly (P <0 . 0 0 1a n dP <
0.001, respectively) reversed CCI induced the paw with-
drawal threshold decreases (Figure 3B), while TC-2559
at 0.3 mg/kg had no significant effect (n = 6, P = 0.051).
The analgesic effect of TC-2559 was rapid onset with
the maximal response proximally at 5 and 20 min after
administration for 1 mg/kg and 3 mg/kg doses, respec-
tively, and the effect was also short lasting, lasted for
less than 40 min after injection (Figure 3B), which was
consistent with our bioavailability study.
In contrast, in the contralateral hind paw, TC-2559
had no effect on the sensory response threshold at the
mid (1 mg/kg, i.p.; P = 0.772, n = 6) and lower (0.3 mg/
kg, i.p.; P =0 . 5 9 1 ,n=6 )d o s e st e s t e d ,b u ts i g n i f i c a n t l y
enhanced the paw withdrawal threshold to above the
control level while given (i.p.) with higher dose at 3 mg/
kg (P = 0.002, n = 6) (Figure 3C).
In order to confirm that the analgesic effect of TC-2559
was due to activation of a4b2 nAChR subtype, the selec-
tive a4b2 subtype antagonist DHbE was employed. Pre-
treatment with DHbE (2 mg/kg, i.p.) fully inhibited the
analgesic effect induced by 3 mg/kg TC-2559 on both
inpsi- and contra-lateral hind paw of CCI rats (P <0 . 0 0 1
and P = 0.003, respectively; Two-way ANOVA; n = 6 in
either groups) (Figure 3D, E). DHbE alone had no effect
on the allodynia induced by CCI (P =0 . 1 1 3 ,n=6 )( F i g u r e
3E). These results indicate that TC-2559, by activation of
a4b2 subtype of nAChRs, has strong antinociceptive prop-
erties on CCI-induced mechanical allodynia.
TC-2559 enhanced inhibitory synaptic transmission by
activation of a4b2 subtype of nAChRs in superficial
dorsal horn neurons
To examine the mechanism underlies the antinociceptive
effects of TC-2559, whole-cell patch-clamp recordings of
superficial dorsal horn neurons in the spinal cord slices
were performed to investigate whether activation of a4b2
nAChR would cause enhanced general inhibition and/or
reduced excitatory pain signal transmission in dorsal
horn neurons, in which nociceptive information is modu-
lated and conveyed to projection neurons.
We first examined the effects of TC-2559 on inhibitory
synaptic transmission of spontaneous inhibitory postsynap-
tic currents (sIPSCs). DNQX (15 μM) was continueously
perfused to block non-NMDA receptor glutamatergic cur-
rents. Membrane potential was held at -70 mV and the
IPSCs were observed as inward currents due to the chlor-
ide-based intra-pipette solution. sIPSCs were observed in
approximately 88% (n = 101/115) neurons tested.
As shown in Figure 4, perfusion of TC-2559 (2 μM)
resulted in a rapid and significant increases in sIPSC fre-
quency in majority of the neurons (18 out of 21, charac-
terized as at least 20% increase of the sIPSC frequency to
above the baseline activities, see method section) tested.
As a whole group, TC-2559 increased the sIPSC fre-
quency from 0.65 ± 0.20 Hz of the baseline control to
1.30 ± 0.39 Hz during TC-2559 perfusion (P =0 . 0 1 2 ,n=
Figure 2 Effect of TC-2559 on formalin-induced biphasic
nociceptive responses in mice. A, Traces showing intraperitoneal
injection of TC-2559 (1, 3, 10 mg/kg) dose dependently suppressed
formalin induced progressive biphasic pain behavior score; B, Bar
histogram showing the group data of antinociceptive effect of TC-
2559 on formalin induced paw lift-licking time in both early 1st
phase (0-5 min) and late 2nd phase (5-30 min) of mice formalin
model. *P < 0.05, **P < 0.01 compared with vehicle saline control
(two-way ANOVA followed by the Holm-Sidak test).
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Page 3 of 13Figure 3 TC-2559 dose dependently reduced CCI-induced neuropathic pain in rats. A, chart showing the progressive change of the paw
withdraw threshold in both ipsilateral and contralateral hind paw before and after CCI injury. Note the enhanced mechanical allodynia in
ipsilateral hind paw but not the contralateral uninjured hind paw. B-C, Traces showing TC-2559 (i.p.) dose dependently reversed CCI-induced
mechanical allodynia in both ipsilateral (B) and contralateral (C) hind paws of CCI rats (n = 6 for each group). Note: at 1 mg/kg dose, TC-2559
only inhibited the mechanical allodynia in CCI hind paw (ipsilateral). D-E, Traces showing DHbE (2 mg/kg, i.p.) reversed TC-2559 (3 mg/kg, i.p.)
induced mechanical allodynia inhibition in both ipsilateral and contralateral hind paws of the CCI rats (n = 6 for each group). *P < 0.05, **P <
0.01 and ***P < 0.001 compared with saline.
#P < 0.05 and
###P < 0.001 compared with 3 mg/kg TC-2559. (two-way ANOVA followed by the
Holm-Sidak test).
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Page 4 of 1321) (Figure 4B, D). In contrast, TC-2559 (2 μM) had no
significant effect on sIPSC amplitude (34.92 ± 4.59 pA vs
49.32 ± 11.60 pA, before and during TC-2559 perfusion,
respectively) (P = 0.090, n = 21) (Figure 4C, E).
DHbE( 2μM) applied alone had no effect on both
sIPSC frequency and amplitude (99.7 ± 6.0% and 104.5
± 9.9% of the control value, respectively; n = 4), but
completely blocked TC-2559 (2 μM) induced sIPSC fre-
quency enhancement (1.33 ± 0.36 Hz vs 1.36 ± 0.38 Hz,
before and during TC-2559 perfusion, respectively) (P =
0.687, n = 12) (Figure 5).
In addition, we also tested the effects of 10 μMT C - 2 5 5 9
on sIPSCs and the result was similar as that of 2 μM TC-
2559. Bath application of TC-2559 (10 μM) increased the
frequency of sIPSCs in 8 out of 10 (80%) neurons tested.
As a whole group, sIPSC frequency were increased from
1.39 ± 0.39 Hz of the baseline control to 2.10 ± 0.63 Hz
during TC-2559 perfusion (P = 0.041, n = 10), but without
Figure 4 TC-2559 enhanced the frequency of sIPSCs in the superficial dorsal horn of the spinal cord slices. A, Whole-cell Patch-clamp
recording of sIPSCs in a substantia gelatinosa (SG) neuron in the presence of 15 μM DNQX before and during bath application of 2 μM TC-2559.
The holding voltage is -70 mV. B-C, Normalized rate histogram showing the sIPSC frequency (B) and amplitude (C) before and during bath
application of 2 μM TC-2559. D-E, Application of TC-2559 (2, 10 μM) significantly enhanced the frequency of sIPSCs, but not the amplitude. *P <
0.05 (paired t test).
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vs 34.67 ± 7.21 pA, before and during TC-2559 perfusion,
respectively) (P = 0.200, n = 10).
These results indicate that acute application of TC-
2559 enhanced inhibitory neurotransmission on spinal
dorsal horn neurons by activation of a4b2 nAChRs.
TC-2559 had no significant effect on excitatory synaptic
transmission in superficial dorsal horn neurons
To test whether activation of a4b2 nAChRs by TC-2559
had any effect on excitatory neurotransmission within
spinal dorsal horn, we then performed whole-cell patch-
clamp recordings of spontaneous excitatory postsynaptic
currents (sEPSCs) in superficial dorsal horn neurons in
rat spinal cord slice. Membrane potential was voltage
clamped at -70 mV.
Bath application of TC-2559 (2 μM) had neither effect
on the sEPSC frequency (99.9 ± 8.2% of the baseline
control) (P = 0.912, n = 18) nor on the sEPSC amplitude
(95.1 ± 4.3% of the baseline control) (P = 0.196, n = 18),
as shown in Figure 6. These results indicate that acute
local activation of a4b2n A C h R sb yT C - 2 5 5 9h a sn o
effect on excitatory neurotransmission in neurons in the
spinal superficial dorsal horn.
Discussion
The animal pain behavior results from the present study
s u g g e s tt h a ts e l e c t i v ea4b2 nicotinic receptor agonist
Figure 5 TC-2559 enhances sIPSCs by activation of a4b2 subtype of nAchRs. A, Sample traces of sIPSCs recorded from a lamina II neuron
in the presence of 15 μM DNQX and 2 μMD H bE before (left) and during bath application of 2 μM TC-2559 (right). Membrane potential was
clamped at -70 mV. B-C, Normalized rate histogram showing the sIPSC frequency (B) and amplitude (C) before and during bath application of 2
μM TC-2559 in the presence of 2 μMD H bE (n = 12). D-E, In the presence of 2 μMD H bE, 2 μM TC-2559 had no significant effects on both the
frequency (D, P = 0.6865, n = 12) and amplitude (E, P = 0.0978, n = 12) of sIPSCs (Paired t test).
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Page 6 of 13TC-2559 has analgesic property, and in vitro spinal cord
slice patch clamp recording results indicate that this
analgesic property is probably medicated by selective
enhancement of inhibitory neurotransmission in the
spinal dorsal horn via activation of a4b2s u b t y p eo f
nicotinic receptors. This conclusion is based on the
observation that: 1) In in vivo animal pain models, TC-
2559 inhibited both intraplantar formalin injection
induced biphasic nociceptive responses and CCI-induced
mechanical allodynia; 2) In in vitro spinal cord slices,
TC-2559 significantly enhanced inhibitory synaptic
transmission, but has no effect on the excitatory synap-
tic transmission.
Bioavalaibility of TC-2559
Similar to what previously reported [16], brain exposure
data of TC-2559 was obtained first as a guidance for
our later in vivo and in vitro studies. The present brain
exposure result demonstrated that TC-2559 at 3 mg/kg
(i.p.) produced an initial peak whole brain concentration
of about ~4 μM (15 min after injection), which quickly
declined to ~2 μM at the 30 min point. The elimination
of TC-2559 was fast with a half life of ~20 min which
was similar to that of given by i.v. shown previously
[16]. Since cerebral-spinal fluid is similar, we assumed
that the spinal concentration of the TC-2559 after i.p.
administration would be as the same as in brain. TC-
Figure 6 TC-2559 has no effect on sEPSCs in the superficial dorsal horn of the spinal cord slices. A, Whole-cell voltage-clamp (Vh =- 7 0
mV) recording of sEPSCs in a SG neuron before and after bath application of 2 μM TC-2559. B-C, Normalized rate histogram showing the
mEPSC frequency (B) and amplitude (C) before and during bath application of 2 μM TC-2559 (n = 18). D-E,2μM TC-2559 had no significant
effect on both the frequency (D, P = 0.3065, n = 18) and amplitude (E, P = 0.7442, n = 18) of sEPSC (Paired t test).
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neuronal nAChR agonist [13] and selective for a4b2
subtype both in vitro [14,16] and in vivo [14,16]. The
EC50 for TC-2559 to evoke excitation in VTA slice was
found to be of 0.6 μM and TC-2559 is ineffective on a7
and a3b2 receptors up to 10 μM, and weakly effective
on a2b4, a4b4a n da3b4 receptors, with EC50’si nt h e
range of 10 - 30 μM [14]. Thus, at the 3 mg/kg i.p. dose
for rat CCI study and 2 μMd o s ef o rin vitro brain slice
experiment used in this study, TC-2559 is likely to be
selective for the a4b2 nicotinic receptor subtype.
Antinociceptive effects of TC-2559 in neuropathic pain
animal models
Pain initiated or caused by a primary lesion or dysfunc-
tion in the nervous system is called neuropathic pain.
Several animal models of neuropathic pain based on the
induction of neuropathic pain behaviors after induction
of a controlled nerve injury have been developed
[20-22]. The formalin test is a model of injury-produced
pain and is well established for its easier to perform and
to standardize [23,24]. The intraplantar injection of for-
malin results in lifting, licking or other agitation beha-
vior during an early phase, which resembles acute pain,
followed by a late phase representative for neuropathic
pain [24] which is comparable to CCI model. In current
study, we demonstrated that TC-2559 dose-dependently
reduced intraplantar formalin injection induced both
early and late phases of nociceptive behaviors in mice.
The dose-dependent inhibition on the late phase espe-
cially suggested that TC-2559 exerts antinociception
effects on neuropathic pain. Nicotine itself has been
demonstrated to have dose dependent antinociceptive
effects in both the early and late phases of the formalin
test in mice [25-27], and these effects were suggested to
act via a4b2 subtype of nAChRs by using selective a4b2
nAChR antagonists. Thus, our results directly demon-
strated for the first time that activation of a4b2s u b t y p e
of nAChRs by selective agonist could reduce the pain
behavior induced by formalin in mice.
CCI model, which was first set up by Bennett in 1988,
possesses the character of both peripheral and central
sensitization [20]. It shares many common way with the
clinical disease of neuropathic pain, and thus has been
widely used in the field of pain study [28]. To further
examine the antinociceptive action of TC-2559 on neu-
ropathic pain, we then tested the effect of TC-2559 on
CCI model in rat. In current study, in order to standar-
dize the CCI model for our pharmacological study, the
rats used for this study were selected initially by their
pain threshold level during the pre-surgery pain beha-
vioral test. Only those with a basal pain threshold
between 6 and 10 g were chosen for CCI model surgery.
As predicted, 4-7 days after CCI induction, 35% of the
rats showed typical sensitized pain threshold under
mechanical stimulation to be lower than 2 g in ipsilat-
eral foot similar as previously reported [19]. Under this
condition, we demonstrated that TC-2559, at the dose
known selective for a4b2s u b t y p eo fn A C h R sin vivo
[12,13], reversed CCI-induced mechanical allodynia in
all the rats tested. This result is the first time to show
the analgesic role of a4b2 subtype of nAChRs in the rat
CCI model. In addition, our data also showed that the
analgesic effect of TC-2559 was quickly returning to the
control level after injection, which is consistent to our
ADME result of the property of TC-2559 in vivo.O u r
bioavailability study showed that TC-2559 was a com-
pound with fast absorption and quick elimination prop-
erties. The in vivo half life in both brain and serum for
TC-2559 was only about 20 min, which was well
reflected for its short analgesic action in vivo in our cur-
rent study. Thus, our in vivo results demonstrated in
two commonly used animal pain models and in addi-
tion, in two different species (mouse and rat) that TC-
2559 is a potent antinociceptive compound.
In contrast to the antinociceptive action of TC-2559
on injured hindpaw at the doses of 1 and 3 mg/kg,
TC2559 at the dose of 1 mg/kg had no effect on the
paw withdrawal threshold in the contralateral hind paw.
However, when the drug dose was increased to 3 mg/kg,
TC-2559 significantly increased the paw withdrawal
threshold in the contralateral hind paw, along with on
ipsilateral hindpaw, compared to that of vehicle control.
This effect suggests that over activation of a4b2 subtype
of nAChR by using high dose of TC-2559 may suppress
the basal sensation of spinal cord sensory transmission.
It is consistent with the results obtained in a previous
study, where a low dose of nicotine (10 nmol i.t.) or epi-
batidine (0.3 nmol i.t.) has no effect in sham animals but
is antiallodynic in peripheral nerve injury mice [11].
Both results suggest that the injured peripheral nerve is
more sensitive to nicotinic receptor activation, which
may indicate of an upregulation of nicotinic receptors
after injury. This has given a therapeutical window to
reduce sensitized pain threshold for nicotinic drugs such
as TC-2559. Since the analgesic effect of TC-2559 on
ipsilateral hindpaw was observed at the dose as low as 1
mg/kg, our current results indicated that the therapeutic
window for TC-2559 on pain release might be likely
between 1 and 3 mg/kg (i.p.) doses in rats. It suggests
that the ligand acts as selective a4b2 subtype of nAChR
agonist may be developed to have a clinically acceptable
therapeutical window between pain signal sensitivity and
normal sensory signal transmission.
DHbE, a widely used compound served as a selective
a4b2 nAChR antagonist [12,13], reversed the antinoci-
ceptive action of TC-2559 in rat CCI model in this
study, while DHbE applied alone had no significant
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results suggest that the antinociceptive effect of TC-
2559 on neuropathic pain is indeed mediated by activa-
tion of a4b2 subtype of nAChRs. In several previous
studies in rats, intrathecal injection of DHbEa l o n eh a d
no effects while they blocked the nociceptive or antino-
ciceptive effects of the nicotinic agonists [29,30]. These
are consistent with our present observation. In addition,
in our in vitro studies in the spinal cord slices, DHbE
alone also had no significant effect on sIPSCs, which is
consistent with our in vivo experiments.
However, the lack of effect of DHbE in rats seems
contradictory with studies performed on mice. Rashied
et al. demonstrated that bath application of DHbE
induces a decrease in the frequency of IPSCs in two
third of dorsal horn neurons in mice [12]. Also, i.t.
injection of DHbE induces mechanical allodynia in mice
[11,12]. These differences in mice and rats are likely due
to species differences. We hypothesis that the Ach
release level in mice might be higher than that in rats.
However, we choose to perform behavior experiments
on different species of animals is because this study was
designed to test whether the selective agonist of a4b2
subtype of nAChR (TC-2559) has antinociceptive effects
and its possible mechanism, thus to test whether the
agonist of a4b2 subtype of nAChR is capable to be
developed as new common analgesic drug for treatment
of neuropathic pain. It would be better to know whether
TC-2559 could have analgesic effects on species known
to have differences since finally it may be used on
human beings. Therefore, we choose to perform beha-
vior experiments (formalin and CCI) on different species
of animals. Our results of formalin test and CCI demon-
strated that TC-2559 has analgesic effects on both mice
and rats, despite they have differences.
Thus, our current study is the first to demonstrate, by
using selective a4b2 nAChR agonist (TC-2559), that
direct stimulation of a4b2 subtype of nAChRs has
strong antinociceptive effects in classic neuropathic pain
animal models.
Spinal mechanisms of antinociceptive effects of TC-2559
The inhibitory interneurons in the spinal dorsal horn
are crucial for maintaining normal input intergration
and are localized throughout the spinal dorsal horn
[31,32]. The neuronal pathways mediating allodynia/
hyperalgesia in spinal dorsal horn are normally under
strong inhibitory regulation [33-35]. Since a4b2s u b t y p e
of nAChRs were reported to be preferentially expressed
in the inhibitory interneurons in the spinal dorsal horn
[36], we hypothesized that activation of a4b2 subtype of
nAChRs by TC-2559 would excite those inhibitory
interneurons expressing a4b2 nAChRs. In turn, the pain
input sensory pathway between primary afferent fibers
and lamina I nociceptive specific neurons in spinal dor-
sal horn would receive more inhibitory control after
activation of a4b2 subtype of nAChRs. Indeed, our
r e s u l t ss h o w e dt h a tT C - 2 5 5 9 ,as e l e c t i v ea4b2n A C h R
partial agonist [14], significantly enhanced the sIPSC fre-
quency in majority of the spinal superficial dorsal horn
neurons tested. This enhancement could be fully antag-
onized by a selective a4b2 nAChR antagonist (DHbE)
indicated that TC-2559 was indeed activated a4b2
nAChRs in spinal dorsal horn. These results suggest
that activation of a4b2 nAChRs would generally
increase the inhibitory tone in the spinal dorsal horn,
thus may regulate both the sensory input and signal
integration in this region.
Hyperalgesia is mediated, in spinal cord level, by
enhanced pain signal transmission and reduced local
inhibition [35,37,38]. However our data showed that
TC-2559 by activation of a4b2n A C h Rh a dn os i g n i f i -
cant effect, in contrast to increase of inhibitory trans-
mission, on the excitatory neurotransmission in spinal
dorsal horn neurons. This result is consistent with a
previous report that nicotine enhances excitatory synap-
tic transmission in the spinal dorsal horn by a7 [39] but
not by a4b2 nAChRs. This is further supported by the
finding that a4b2 subtype of nAChRs expressed prefer-
entially in the inhibitory interneurons in the spinal dor-
sal horn [36]. Thus, as expected, activation of these
receptors would have predominant effect on the inhibi-
tory, rather than excitatory neurotransmitter release in
this region. This result suggests that the antinociciptive
effect of TC-2559, by activation of a4b2n A C h R s ,i s
likely due to solely modulation of the inhibitory circuits
within the spinal dorsal horn to enhance the basal inhi-
bition, but not affecting either excitatory sensory input
or excitatory interneuron function.
Although the methods that by patch clamp recording
on visually identified spinal superficial dorsal horn neu-
rons could not resolve cell identity, the high prevalence
of enhancement on sIPSCs by TC-2559 (~85% of neu-
rons with > 20%of increase on sIPSC frequency) sug-
gests that this type of inhibitory modulation in spinal
superficial dorsal horn might be common to multiple
populations of the neurons in this region of the spinal
cord. This is consistent with the action of nicotine with
which GABAergic synaptic transmission was enhanced
in 86% of neurons tested in the spinal dorsal horn [40].
Thus it suggests that TC-2559 would enhance the gen-
eral inhibition in the superficial dorsal horn neurons by
activation of a4b2 subtype of nAChRs.
Although our results clearly demonstrated that TC-
2559 by activation of a4b2n A C h R st oe n h a n c et h e
basal inhibition in spinal dorsal horn neurons which in
turn, as expected, to reduce the pain related peripheral
sensory input at the spinal cord level, we can not rule
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of a4b2 nAChRs localized in the regions other than
spinal cord dorsal horn, while tested in in vivo pain ani-
mal models by systemic application of TC-2559. How-
ever, since spinal dorsal horn is an important pain
signal primary integration region, we hypothesis that
activation of a4b2 nAChRs localized in the spinal dorsal
horn by TC-2559 to enhance the over all inhibitory tone
is one of the major contributor for TC-2559’s antinoci-
ciptive action.
Functional implication
Spinal dorsal horn neurons including those mediating
allodynia/hyperalgesia signals are normally under
strong inhibitory regulation [33-35]. And any mechan-
ism to release those inhibition on the pain signaling
pathway in the spinal dorsal horn opens the gate to
pathological pain sensory input to spinal dorsal horn
neurons [33,35,41], which would cause the chronic
pain hypersensitivity [11]. Reports have shown that dis-
ruption of this inhibition by blockade of a4b2s u b t y p e
of nAChRs induced thermal and mechanical hyperalge-
sia in both normal rats [29,30] and naive mice [12],
which indicates that a4b2 subtype of nAChRs play a
crucial modulatory role to maintain the tonic inhibi-
tion in spinal dorsal horn for sensory and/or pain sig-
nal input. The data from our current study were
indeed showing that direct activation of a4b2 subtype
of nAChRs by agonist of TC-2559 did exert antinoci-
ceptive effects in pathological pain animal models of
both formalin test and CCI possibly by enhancing the
inhibitory neurotransmission in spinal dorsal horn. In
addition, we showed that TC-2559, acting as a selective
a4b2 subtype of nAChR agonist, deferentially
enhanced inhibitory neurotransmission in spinal dorsal
horn neurons but not affecting excitatory neurotrans-
mission. This property gives the hope that a4b2
nAChRs agonist based analgesic drug might have fewer
side effects than that of currently marketed pain
relieves, in terms of the spinal cord level. However,
when given intracerebroventricularly (i.c.v.) and intra-
cisternally (i.c.), TC-2559 has been reported to induce
an increase in blood pressure and renal nerve activity
[42]. What’s more, we have also previously demon-
strated that TC-2559, while given intravenously, acti-
vates dopaminergic neurons in the VTA and suppress
hippocampal long term potentiation [29,30] in anaes-
thetized rats. Thus TC-2559 itself is therefore likely to
have numerous physiological functions beside analge-
sia. Since TC-2559 is an selective partial a4b2n A C h R
agonist [29,30], developing more potent agonist selec-
tive for a4b2 nAChRs may be one of the directions for
developing nicotinic receptor based analgesic drug.
Conclusions
The antinociciptive property of a4b2s u b t y p eo f
nAChRs has been previously reported with the aid of
the selective antagonist [12,29,30]. Here, we demon-
strated for the first time by using a selective a4b2s u b -
type of nAChR partial agonist TC-2559, that direct
stimulation of the a4b2 nAChRs has analgesic effect on
pathological pain. Our behavioral and electrophysiologi-
cal data indicated that TC-2559 exerts antinociception
effects on pathological pain models, and enhancement
of spinal dorsal horn inhibitory neuronal transmission
via activation of a4b2 subtype of nicotinic receptors is
one of the underlying mechanisms. Although the ADME
property (fast elimination rate), the narrow therapeutic
window and numerous other physiological function
beside analgesia makes TC-2559 with limited drug abil-
ity, our results are still the first direct evidence to
strongly support the notion that the agonist of a4b2
subtype of nAChR is capable to be developed as new
analgesic drug for treatment of neuropathic pain with
less side effects.
Methods
Experimental animals
Experiments were performed on adult male mice (body
weight 15-30 g), adult male (body weight 200-220 g)
and young (postnatal days 14-21) SD rats for formalin
test, CCI, brain exposure and in vitro electrophysiologi-
cal experiments, respectively. All the animals were pur-
chased from Shanghai Experimental Animal Center,
Chinese Academy of Sciences, Shanghai. Animals were
kept on a 12 hour light: dark cycle with a room tem-
p e r a t u r eo f2 3±1 ° Ca n dr e c e i v e df o o da n dw a t e rad
libitum. All procedures of the experiments were
approved by the Committee of Animal Use for Research
and Education of Fudan University, and all efforts were
made to minimize the number of animals used and
their suffering, in accordance with the ethical guidelines
for animal research.
Brain exposure experiments
A total of 8 male Sprague Dawley rats were used in
these experiments. Rats were killed by overdose of
urethane (5 g/kg, i.p.) at different time points (0.25, 0.5,
1 and 2 h) after TC-2559 (3 mg/kg, i.p.) administration.
Brain tissues were quickly removed for in vitro measure-
ments, similar as previously reported [12]. Brain samples
were prepared by the addition of twice the volume (ml)
of water to weight (g) of brain cortex, followed by
homogenisation to produce a smooth suspension.
Homogenised brain cortex samples (500 μl) were then
extracted with methyl-t-butyl ether and centrifuged. The
solvent layer was transferred to clean tubes and
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d i s s o l v e di n5 0 %m e t h a n o la n da n a l y s e du s i n gl i q u i d
chromatography and a Sciex API 3t Mass Spectrometer,
with turbo-ionspray in positive ion MRM mode, for
detection. Data were calculated using MacQuan 1.4. In
order to estimate the total brain concentration, 1 g of
t h eb r a i nt i s s u ew a sa s s u m e dt ob ee q u i v a l e n tt ob e1
ml in volume.
Formalin test
Classic formalin test was performed as previously
described [18,43]. Briefly, after 15 minutes of stabilizing
period in an experimental beaker, mice received intra-
plantar injection of 5.0% formalin solution (50 μl, saline
vehicle) to the right hindpaw, and placed back to the
beaker immediately for nociceptive behavior observation.
Either vehicle (saline) or different doses of TC-2559 (1,
3, 10 mg/kg) were administered intraperinatally 5 min
before formalin injection. Animals were sacrificed
immediately at the end of the study by the intraperinatal
injection of over dose of urethane and neck
displacement.
Nociceptive behavior elicited by formalin injection,
such as lifting, licking and biting of the injured paw
were recorded and timed for every 5-minute time bins
manually for 45 minutes continuously. The formalin
pain score was calculated using the following formula as
previous reported [43]: formalin pain score = [seconds
spent on paw lifting + 2 × (seconds spent licking or bit-
ing injected paw)]/300. Data were then analyzed for
early (0-10 mins) and late (11 - 4 5m i n s )p h a s e sa sp r e -
vious reported [43].
Chronic constriction injury (CCI) of the sciatic nerve and
the measurement of mechanical allodynia
Rats were deeply anesthetized with 2% pentobarbital
sodium (40 mg/kg, i.p.), judged by absence of paw with-
draw reflex. CCI operation was performed as previously
described [19] in a sterilized environment. After the sur-
gery, animals were retuned to their home cages for
recovery, for at least 5 days. The paw withdrawal thresh-
old (PWT) was determined using a calibrated series of
von Frey hairs (Stoelting, IL, USA) ranging from 1 to 26
g. Before the behavioral tests, animals were allowed to
acclimate for 30 min in the animal facilities. A series of
9 calibrated von Frey hairs were applied in ascending
order (1, 1.4, 2, 4, 6, 8, 10, 15 and 26 g). A particular
hair was applied until it buckled. This was maintained
for approximately 2 sec. A trial consisted of application
of a von Frey hair to the hind paw five times at 5-sec
intervals. If withdrawal did not occur during five appli-
cation of a particular hair, the next larger hair in the
series was applied in a similar manner. When the hind
paw was withdrawn from a particular hair in three out
of five consecutive applications, the value of that hair in
grams was considered to be the withdraw threshold.
After the threshold was determined for one hindpaw,
the same testing procedure was repeated on the other
hindpaw at 5-min interval. The rats received continued
measurement of PWT for 3 days before CCI surgery.
Rats with PTW at between 6 g - 10 g for both paws
were chosen for CCI operation in this study. Assessment
of PWT began 5 days after surgery. Either drugs or
vehicle were tested only when the PTW after CCI
reached to a stable level as shown in Figure 2A. In drug
testing day, PWT was measured once 10 min before
TC-2559 at different doses or saline injection (i.p.), and
3 times after drug administration at 15 min inter test
interval.
Preparation of spinal cord slices
As we previously described [44], young SD rats (postna-
tal days 14-21) were deeply anesthetized with diethyl
ether, and for spinal nerve blocking, about 1 ml lido-
caine (5 ml: 0.1 g) was injected to both sides of lumbar
vertebrae (L4-5). Laminectomy was performed from
mid-thoracic to low lumbar levels and the cord was
quickly removed to cold modified artificial cerebrospinal
fluid (ACSF), which was containing (in mM): NaCl, 80;
KCl, 2.5; NaH2PO4, 1.25; CaCl2,0 . 5 ;M g C l 2,3 . 5 ;
NaHCO3, 25; sucrose, 75; ascorbate, 1.3; sodium pyru-
vate, 3.0 with pH at 7.4 and osmolarity at 310.5 mOsm,
a n do x y g e n a t e dw i t h9 5 %O 2 and 5% CO2.. Transverse
500 μm slices were obtained. Slices were then incubated
for at least 1 h at 35°C in a solution that consisted of:
( i nm M )N a C l ,1 2 5 ;K C l ,2 . 5 ;C a C l 2,2 ;M g C l 2,1 ,
NaH2PO4, 1.25; NaHCO3, 26; D-glucose, 25; ascorbate,
1.3; sodium pyruvate, 3.0 with pH at 7.4 and osmolarity
at 324.5 mOsm, and oxygenated with 95% O2 and 5%
CO2. The slice was then transferred into a recording
chamber and perfused with oxygenated recording solu-
tion at a rate of 5 ml min
-1 prior to electrophysiological
recordings at room temperature.
Whole-cell patch clamp recordings from spinal cord slices
N e u r o n sw e r ei d e n t i f i e db yi n f rared differential inter-
ference contrast (IR-DIC) video microscopy with an
upright microscope (Nikon, LV-TV) equipped with a
40×, 0.80 NA water-immersion objective and a CCD
camera (IR-1000E, USA). Patch pipettes (5-10 MΩ)
from borosilicate glass (Sutter Instruments, Novato,
CA, USA) were made on a horizontal micropipette
puller (P-97, Sutter Instruments, Novato, CA, USA).
The pipettes used for recording inhibitory currents
were filled with (in mM): 140 CsCl, 2 MgCl2,1C a C l 2,
1 EGTA, 10 HEPES, 5 K-ATP, 0.1 GTP, pH = 7.4.
Using these solutions, at theh o l d i n gp o t e n t i a lo f- 7 0
mV, inhibitory currents appear as inward deflection.
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t h es p i n a ld o r s a lh o r nn e u r o n s ,1 5μMD N Q Xw a s
included in the external bath solution to block non-
NMDA receptor glutamatergic currents. The pipette
solution used for recording excitatory currents con-
tained (in mM): potassium gluconate 120, KCl 20,
MgCl2 2, Na2ATP 2, NaGTP 0.5, HEPES 20, EGTA
0.5, pH 7.28 with KOH, measured osmolarity 300 mM.
Data were acquired using an MultiClamp 700B patch-
clamp amplifier (Axon Instruments, USA). Access (ser-
ies) resistances of all cells were monitored and
recorded every one minute throughout the experiment
by applying a 2 mV hyperpolarizing pulse for 2 ms.
Only those cells that showed < 20% change in access
resistance over the period of experiments were
included in the data analysis. Responses were low-pass
filtered on-line at 2 kHz, digitized at 5 kHz, and ana-
lyzed off-line using Clampfit 10.0 and Mini 60 soft-
ware. Membrane potential was held at -70 mV and all
recordings were performed at room temperature.
Drugs were bath applied by exchanging perfusion solu-
tion containing a known drug concentration without
altering the perfusion rate and the time period for
drug reach the recorded spinal slice was estimated at
~40s. IPSCs or EPSCs recorded 1 min before drug
application were served as baseline control, and drug
effects were assessed during the second minute after
drug application. When normalized, data were
expressed as % of control. The drug effect on either
IPSCs or EPSCs was defined as “increase"or “decrease”
if the variation compared with control were ± 20%,
respectively, as previous reported [42].
Reagents
Dihydro-b-erythroidine (DHbE), bicuculline methiodide,
dihydro-h-erythroidine hydrobromide 6,7-dinitroqui-
noxaline-2,3-dione (DNQX), strychnine, Ethylene glycol-
bis(2-aminoethylether)-N, N, N’,N ’-tetraacetic acid
(EGTA), HEPES, K-ATP and Mg-GTP were all pur-
chased from sigma. TC-2559 was a gift from Eli Lilly
Company. For in vivo studies, TC-2559 and DHbEw e r e
dissolved in normal saline. For in vitro experiments, all
of the drugs except DNQX (initially dissolved in
dimethylketone) were dissolved in deionized water and
prepared as stock solutions and diluted to the required
concentration (1:1000) with ACSF. All drugs were bath
applied in in vitro experiments.
Data analysis and statistics
Data were expressed as mean ± s.e.m. Effects of drugs
on behavior tests between two groups were compared
with two-way ANOVA followed by the Holm-Sidak test
for time course measures and t-test for point-to-point
comparison. Paired t-test or unpaired t-test was used for
data from in vitro electrophysiology experiments. P <
0.05 was considered statistically significant.
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